Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.019 | 0.7 |
mRNA | Sorafenib | FIMM | pan-cancer | AAC | -0.059 | 0.7 |
mRNA | GSK525762A | CTRPv2 | pan-cancer | AAC | 0.01 | 0.7 |
mRNA | selumetinib:navitoclax (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.013 | 0.7 |
mRNA | BRD-K27986637 | CTRPv2 | pan-cancer | AAC | 0.026 | 0.7 |
mRNA | BRD-K58730230 | CTRPv2 | pan-cancer | AAC | -0.027 | 0.7 |
mRNA | BIBW2992 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.7 |
mRNA | Imatinib | FIMM | pan-cancer | AAC | -0.059 | 0.7 |
mRNA | Bicalutamide | GDSC1000 | pan-cancer | AAC | 0.011 | 0.7 |
mRNA | BRD-K34099515 | CTRPv2 | pan-cancer | AAC | -0.027 | 0.7 |